Dissacharide Patents (Class 514/53)
-
Patent number: 10279050Abstract: The invention provides a class of sucrose ester based cationic lipids and preparation method thereof. The vector prepared using the cationic lipid can be used to deliver nucleic acid. The sucrose ester based cationic lipid is prepared by using a chemical synthesis method in the invention, wherein the synthesis method is simple, and has a relatively high product yield. A composition, including suspension, emulsion, micelle and liposome and the like, can be prepared by mixing the sucrose ester based cationic lipid compound of the invention with a co-lipid. Sucrose ester based cationic lipid complex can be prepared by using the said composition and nucleic acid, which has advantages such as simple preparation, low toxicity and high transfection efficiency, and is a novel and highly efficient gene vector.Type: GrantFiled: June 25, 2015Date of Patent: May 7, 2019Assignee: DALIAN NATIONALITIES UNIVERSITYInventors: Shubiao Zhang, Defu Zhi, Shaohui Cui, Yinan Zhao, Quan Zhou
-
Patent number: 10265312Abstract: A method of preventing post-operative endophthalmitis involves injecting a colored antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination thereof, and the coloring agent being preferably a cobalamin (e.g., cyanocobalamin).Type: GrantFiled: August 13, 2018Date of Patent: April 23, 2019Inventor: Jason Ahee
-
Patent number: 10188661Abstract: Described herein is a novel dosage regimen, and related uses and methods, for a prostaglandin FP receptor agonist (PFPRA) compound topically administered to the skin. The dosage regimen is useful for reduction of subcutaneous fat, for example, in patients who suffer from local excesses of subcutaneous fat. A particular advantage of the dosage regimen is the ability to reduce composition exposure and thereby promote convenience and comfort, while maintaining the desired exposure and therapeutic effect in subcutaneous fat. Further provided are kits according to the novel dosage regimen, comprising a PFPRA composition and instructions for use.Type: GrantFiled: June 24, 2015Date of Patent: January 29, 2019Assignee: Topokine Therapeutics, Inc.Inventors: Michael S. Singer, Murat V. Kalayoglu
-
Patent number: 10166200Abstract: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.Type: GrantFiled: June 8, 2017Date of Patent: January 1, 2019Assignee: NuvOx Pharma LLCInventors: Evan C. Unger, Edmund R. Marinelli
-
Patent number: 10159635Abstract: The present invention provides cosmetic and pharmaceutical compositions and therapies capable of reducing skin pigmentation and valuable in treating and managing disorders of skin pigmentation. The invention uses safe and well tolerated non-digestible oligosaccharides as the active agents providing numerous advantages over the harsh chemicals of previously available compositions.Type: GrantFiled: March 19, 2013Date of Patent: December 25, 2018Assignee: Curapel (Scotland) LimitedInventors: Catherine O'Neill, Ralf Paus
-
Patent number: 10130583Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.Type: GrantFiled: April 14, 2014Date of Patent: November 20, 2018Assignee: Pegion Operations LimitedInventor: Claes Thulin
-
Patent number: 9937134Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.Type: GrantFiled: July 20, 2015Date of Patent: April 10, 2018Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert Lewis
-
Patent number: 9889176Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.Type: GrantFiled: August 17, 2011Date of Patent: February 13, 2018Assignee: YAQRIT LIMITEDInventors: Rajiv Jalan, Naina Shah
-
Patent number: 9854826Abstract: The invention discloses an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide. Food product, especially infant formula, comprising said oligosaccharide mixture.Type: GrantFiled: November 21, 2011Date of Patent: January 2, 2018Assignee: Nestec S.A.Inventors: Norbert Sprenger, Jean-Richard Neeser
-
Patent number: 9763969Abstract: The present invention describes compositions and related methods and kits for treating a variety of inflammatory conditions and infections. The therapeutic compositions include certain hyaluronidases capable of generating hyaluronan disaccharides when combined with hyaluronan, and/or the hyaluronan disaccharides themselves, and/or inflammatory hyaluronidase inhibitors. The invention further discloses the use of hyaluronidase inhibitors to treat certain infections in an individual.Type: GrantFiled: April 3, 2014Date of Patent: September 19, 2017Assignee: Cedars-Sinai Medical CenterInventors: George Liu, Pierre Kyme
-
Patent number: 9744188Abstract: Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase ? (RPTP?), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTP? and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTP?. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTP?. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.Type: GrantFiled: February 17, 2012Date of Patent: August 29, 2017Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDInventors: John G. Flanagan, Yingjie Shen, Edith Yvonne Jones, Alexandru Radu Aricescu, Charlotte Hannah Coles
-
Patent number: 9707249Abstract: A trehalulose-containing composition, its preparation and use.Type: GrantFiled: November 20, 2013Date of Patent: July 18, 2017Assignee: SUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURTInventors: Wolfgang Wach, Thomas Rose, Michael Klingeberg, Siegfried Peters, Tillmann Dörr, Stephan Theis, Jörg Kowalczyk, Stephan Hausmanns
-
Patent number: 9700523Abstract: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.Type: GrantFiled: August 29, 2014Date of Patent: July 11, 2017Assignee: NuvOx Pharma LLCInventors: Evan C. Unger, Ed Marinelli
-
Patent number: 9664677Abstract: A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex.Type: GrantFiled: April 19, 2011Date of Patent: May 30, 2017Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Michael S. Strano, Jingqing Zhang, Paul Walter Barone, Daniel A. Heller, Jong-Ho Kim
-
Patent number: 9655918Abstract: The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.Type: GrantFiled: March 27, 2013Date of Patent: May 23, 2017Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Anna Maria Zanellato, Vincenza Corsa, Giancarlo Carpanese, Monica Campisi
-
Patent number: 9622976Abstract: A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions.Type: GrantFiled: January 17, 2014Date of Patent: April 18, 2017Assignee: Lek Pharmaceuticals d.d.Inventors: Adnan Beso, Igor Legen, Sebastjan Reven
-
Patent number: 9539269Abstract: Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.Type: GrantFiled: December 22, 2011Date of Patent: January 10, 2017Assignee: Abbott LaboratoriesInventors: JoMay Chow, Steven R. Davis, Rachael Buck, Geralyn O. Duska-McEwen, Hawley K. Linke
-
Patent number: 9526602Abstract: A process for applying an adhesion barrier material to the tissue in a surgical site includes steaming the adhesion barrier material, preferably in a warm environment at a temperature of between about 140° F. (60° C.) and about 170° F. (77° C.); air drying the adhesion barrier material until the surface is not tacky; and applying the adhesion barrier material to tissue at a surgical site.Type: GrantFiled: March 17, 2014Date of Patent: December 27, 2016Inventors: Anne Piche-Radley, Della A. Smith, Monica D. Dye
-
Patent number: 9522183Abstract: The present invention provides liposomal compositions for inducing immune tolerance. The compounds typically comprise a liposome displaying a specific antigen and also a binding moiety for a sialic acid binding Ig-like lectin (Siglec)expressed on B cells. The invention also provides methods for inducing tolerance to a protein or polypeptide antigen (e.g., a protein antigen) in a subject. The methods involve administering to the subject a pharmaceutical composition that co-presents both the antigen and a glycan ligand for a Siglec expressed on B lymphocytes.Type: GrantFiled: July 29, 2011Date of Patent: December 20, 2016Assignee: The Scripps Research InstituteInventors: James C. Paulson, Matthew Macauley, David Nemazee
-
Patent number: 9446095Abstract: Provided is a solid composition which has reduced bad taste and offensive odor and provides good taste and flavor, while containing wheat albumin at a high concentration. A solid composition comprising the following components (A) and (B): (A) wheat albumin, and (B) alanine or a salt thereof, wherein a mass ratio of a content of the 0.19-wheat albumin (a) in the solid composition to a content of the alanine or a salt thereof in terms of alanine (b) in the solid composition, [(a):(b)], is from 250:1 to 10:1.Type: GrantFiled: February 13, 2014Date of Patent: September 20, 2016Assignee: KAO CORPORATIONInventors: Aiko Shudo, Nobuteru Ishizuka
-
Patent number: 9326939Abstract: The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses.Type: GrantFiled: July 29, 2011Date of Patent: May 3, 2016Assignee: The Scripps Research InstituteInventors: James C. Paulson, Weihsu Claire Chen, Norihito Kawasaki, Corwin Nycholat
-
Patent number: 9241890Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.Type: GrantFiled: July 12, 2012Date of Patent: January 26, 2016Assignees: SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLE, LABORATOIRES URGOInventors: Laurent Apert, Marielle Bouschbacher
-
Patent number: 9192791Abstract: The present invention relates to a topical composition for use on skin containing theanine derivatives as active components and, more particularly, to a topical composition for use on skin having anti-aging, skin wrinkle repair, skin barrier enhancement, skin immunity enhancement, skin moisturizing, and atopy alleviation effects by containing theanine derivatives as active components.Type: GrantFiled: November 8, 2012Date of Patent: November 24, 2015Assignee: Amorepacific CorporationInventors: Jin Young Lee, Jae Won Yoo, Hyang Tae Choi, Han Byul Kim, Sung Hoon Lee, Ji Seong Kim, Ji Hyun Bae
-
Patent number: 9180208Abstract: Microspheres, typically sterile, inert, silica glass microspheres, are dispersed in a carrier suitable for use relative to the object to be imaged and analyzed. In the case of ophthalmic imaging, an ophthalmically-acceptable gel is used and the resulting composition is dispensed into a mammalian eye. The gel and microspheres dispersed therein coat and conform to the surface of the eye. The microspheres enhance reflectance from the eye which improves signal-to-noise ratio and improves imaging quality.Type: GrantFiled: September 25, 2013Date of Patent: November 10, 2015Assignee: i SONIC Medical CorporationInventor: Pierre Bitoun
-
Patent number: 9161562Abstract: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.Type: GrantFiled: February 9, 2012Date of Patent: October 20, 2015Assignee: Horizon Science Pty LtdInventors: David Kannar, Barry James Kitchen
-
Patent number: 9149043Abstract: The disclosure relates to compositions for treating and/or preventing fire blight in plants or parts thereof, to their methods of production, to concentrates for producing said compositions and to uses and methods based on said compositions.Type: GrantFiled: July 9, 2010Date of Patent: October 6, 2015Inventors: Ulf Abele, Hans Siebenlist
-
Patent number: 9133279Abstract: The invention discloses a cross-linked polymer of at least one carbohydrate component comprising at least one primary alcohol function in particular for the manufacture of a composition which is intended to be applied onto the skin to obtain a tensing and/or toning effect.Type: GrantFiled: July 1, 2005Date of Patent: September 15, 2015Assignee: BASF BEAUTY Care Solutions France S.A.S.Inventors: Eric Perrier, Nabil Abdul-Malak, Julie Saget
-
Patent number: 9101785Abstract: Disclosed is a method of treating seborrhoea by administering to an patient in need thereof a therapeutically effective amount of 2,3-dihydroxypropyl dodecanoate. In particular, the seborrhoea is associated with the skin, including the scalp. The method topically applies a composition containing a therapeutically effective amount of 2,3-dihydroxypropyl dodecanoate to the skin.Type: GrantFiled: December 17, 2010Date of Patent: August 11, 2015Assignee: PIERRE FABRE DERMO-COSMETIQUEInventors: Corinne Dechelette, Redoules Daniel
-
Patent number: 9060529Abstract: The present invention relates to a method of treating a liquid composition containing lacto-N-biose, the method including: preparing a liquid composition containing lacto-N-biose having a pH at 25° C. of not less than 2.0 and not more than 5.5, and heating the liquid composition at a temperature of 65° C. or higher. The present invention can provide a treatment method that enables thermal decomposition of lacto-N-biose to be suppressed when a liquid composition containing lacto-N-biose is heated at a temperature of 65° C. or higher, a liquid preparation containing lacto-N-biose that is treated using the treatment method, a dried product produced from such a liquid preparation containing lacto-N-biose, and a method of producing a product containing lacto-N-biose.Type: GrantFiled: January 31, 2011Date of Patent: June 23, 2015Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Motomitsu Kitaoka, Mamoru Nishimoto, Kanetada Shimizu
-
Patent number: 9056208Abstract: A personal care composition that comprises: a) a sugar infused with at least one additive, in particular, hair and/or skin benefit agent, wherein the infused sugar is coated with a hydrocarbon layer of selected viscosity and melting point; b) at least 10 wt % water, based on the total weight of the composition, wherein the infused and coated sugar is suspended in the composition as a disperse particle phase.Type: GrantFiled: February 7, 2013Date of Patent: June 16, 2015Inventors: Hongjie Liu, Lin Yang, Georgia Shafer
-
Patent number: 9045523Abstract: The present invention is directed to sulphated compounds comprising at least one glycosidic amine group, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof. The present invention is also directed to methods of synthesizing such compounds. Such compounds may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound healing, depression, and other diseases and disorders.Type: GrantFiled: November 14, 2007Date of Patent: June 2, 2015Assignees: PHAROS PHARMACEUTICALS INC., DIOSAMINE DEVELOPMENT CORPORATIONInventors: Michael Peter Seed, Michael Burnet, Hans Hurgen Gutke
-
Patent number: 9040078Abstract: The invention provides a method for treating a subject suffering from a disease of the central nervous system which is associated with an inflammatory response, including, inter alia, multiple sclerosis, Amyotrophic Lateral Sclerosis (ALS), meningitis, Alzheimer's disease, pain, HIV-associated dementia, stroke, traumatic brain injury, encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, cerebral ischemia-induced injury or any combination thereof. This invention further provides for the use of a conjugate, or composition comprising the same, for treating the subject, wherein the conjugate comprises a lipid or phospholipid moiety bonded to a physiologically acceptable monomer, dimer, oligomer, or polymer.Type: GrantFiled: August 17, 2004Date of Patent: May 26, 2015Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventor: Saul Yedgar
-
Publication number: 20150140090Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.Type: ApplicationFiled: January 4, 2013Publication date: May 21, 2015Inventors: Toshihisa Kawai, Kenneth I. Kohn
-
Publication number: 20150141367Abstract: A prebiotic formulation for oral administration to a human comprising 2?-fucosyllactose, 3?-sialyllactose and 6?-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.Type: ApplicationFiled: January 26, 2015Publication date: May 21, 2015Inventor: David Curtis Frantz
-
Publication number: 20150133398Abstract: The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.Type: ApplicationFiled: September 12, 2014Publication date: May 14, 2015Inventors: Andrew J. Ritter, Dennis Savaiano, David Barnes, Todd Klaenhammer
-
Publication number: 20150126472Abstract: The present invention relates to a strain of Serratia plymuthica capable of producing turanose and to the uses thereof.Type: ApplicationFiled: May 15, 2013Publication date: May 7, 2015Applicant: ROQUETTE FRERESInventors: Sophie Defretin, Damien Raeckelboom
-
Patent number: 9023763Abstract: Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants.Type: GrantFiled: April 23, 2012Date of Patent: May 5, 2015Assignee: Isis Innovation LimitedInventors: Ram Sagar, Lucia F. Primavesi, Matthew J. Paul, Benjamin G. Davis
-
Patent number: 9018003Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.Type: GrantFiled: May 12, 2006Date of Patent: April 28, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
-
Patent number: 9006211Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.Type: GrantFiled: August 28, 2013Date of Patent: April 14, 2015Assignee: OPKO Health, Inc.Inventor: Tahir Ahmed
-
Patent number: 9006210Abstract: A method of treating corneal inflammation in a subject includes administering to the subject a therapeutically effective amount of a TLR4 antagonist.Type: GrantFiled: June 15, 2009Date of Patent: April 14, 2015Assignee: Case Western Reserve UniversityInventor: Eric Pearlman
-
Patent number: 9006188Abstract: The present invention provides novel co-crystal forms of dapagliflozin, namely a dapagliflozin lactose co-crystal and a dapagliflozin asparagine co-crystal, to pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating type 2 diabetes.Type: GrantFiled: May 23, 2014Date of Patent: April 14, 2015Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Publication number: 20150098987Abstract: An object of the present invention is to provide a trans-resveratrol derivative that resists isomerization to the cis-form. This object can be achieved by a method for producing a trans-resveratrol polysaccharide, the method comprising the step of bringing a trans-resveratrol glucoside into contact with sugar in the presence of ?-cyclodextrin glucanotransferase.Type: ApplicationFiled: July 11, 2014Publication date: April 9, 2015Inventors: Hiroki HAMADA, Shinichi KOJIMA, Shoji TAKAHASHI, Chiemi MOMOTA
-
Publication number: 20150094278Abstract: The present disclosure provides methods, systems, and instruments for the determination by a physician or medical professional whether a subject is experiencing or has recently experienced an overt HE episode and for grading overt HE episodes as well as methods, systems, instruments and tools for screening for overt HE episodes by a non-medical professional such as a caregiver. Also provided are methods of treating HE episodes and methods of monitoring HE episode treatment that incorporate these methods, systems, instruments, and tools.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI, Marzena JUREK
-
Patent number: 8993740Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.Type: GrantFiled: February 21, 2011Date of Patent: March 31, 2015Assignee: Glycom A/SInventors: István Bajza, Gyula Dekany, Károly Ágoston, Ignacio Figuero-Pérez, Julien Boutet, Markus Hederos, Ferenc Horváth, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Péter Trinka, László Kalmár, Irme Kovács, Sándor Demkó, Ágnes Ágoston, Christian Risinger
-
Publication number: 20150087615Abstract: Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.Type: ApplicationFiled: April 18, 2014Publication date: March 26, 2015Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Shamgar BEN-ELIYAHU, Pini MATZNER, Steven G. REED
-
Publication number: 20150080331Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.Type: ApplicationFiled: August 27, 2014Publication date: March 19, 2015Inventor: Pete ANDERSON
-
Patent number: 8980303Abstract: The invention relates to medicine and pharmacology, more particularly to a pharmaceutical composition in the form of vaginal suppositories for treating candidal vaginitis and vulvovaginitis, containing antimycotics and prebiotics. The contents of the composition for therapeutic use make it possible to achieve the synergistic effect of stimulating the growth of the normal vaginal microflora through the presence of prebiotics and inhibiting the growth and eliminating pathogenic Candida fungi through the presence of modern antimycotics. Furthermore, the composition substantially contains such antimycotics to which representatives of the normal flora, i.e. lactobacilli and bifidobacteria, are insensitive. The method for treating mycetogenous or bacterial vaginosis, vaginitis and vulvovaginitis is carried out with the aid of the antimycotic and prebiotic pharmaceutical composition in a medicinal form for local application.Type: GrantFiled: September 30, 2008Date of Patent: March 17, 2015Assignee: Lugs International Ltd.Inventors: Aleksander Vladimirovich Dikovskiy, Oleg Valentinovich Dorozhko, Anatolievich Bor Rudoi
-
Patent number: 8981079Abstract: A chlorinating agent such as a chloroiminium species is used to remove or neutralize tertiary acetamide present as a contaminant in a tertiary formamide solvent. Tertiary formamide solvent purified or treated in this manner can be used as a reaction vehicle for the chlorination of sucrose-6-acylates, thereby improving the yields of the desired sucralose-6-acylate (an intermediate in the production of sucralose).Type: GrantFiled: June 18, 2010Date of Patent: March 17, 2015Assignee: Tate & Lyle Technology LimitedInventors: James Edwin Wiley, Jr., Mohamad R. Jaber
-
Publication number: 20150071988Abstract: This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and a drug effective for the treatment a mammal as an aerosol and a method of treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the drug alone or up to at least one week.Type: ApplicationFiled: August 6, 2014Publication date: March 12, 2015Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharm
-
Publication number: 20150072952Abstract: The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue.Type: ApplicationFiled: March 14, 2013Publication date: March 12, 2015Inventors: Robert J. Woods, Paul V. Murphy, Loretta Yang, Hannah M.K. Smith, Jenifer Hendel